furosemide has been researched along with Patency of the Ductus Arteriosus in 43 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Twelve risk factors for dTSH were identified on univariate analysis: cesarean section, mechanical ventilation, patent ductus arteriosus (PDA), pneumothorax, and administration of cefotaxime, vancomycin, fluconazole, dopamine, ibuprofen, furosemide, insulin, and packed red blood cells." | 3.85 | Risk Factors for the Development of Delayed TSH Elevation in Neonatal Intensive Care Unit Newborns. ( Almashanu, S; Bier Palmon, R; Eventov-Friedman, S; Flidel-Rimon, O; Golan, A; Kats, N; Keidar, R; Marom, R; Troitzky, M; Zung, A, 2017) |
| " Four had severe hyaline membrane disease and one had chronic bronchopulmonary dysplasia; all received furosemide." | 3.66 | Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants. ( Demers, LM; Friedman, Z; Maisels, MJ; Marks, KH; Uhrmann, S, 1978) |
| "Furosemide is known to increase renal prostaglandin synthesis." | 2.75 | Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. ( Byun, SY; Chang, JY; Chung, ML; Kim, EA; Kim, HY; Kim, KS; Lee, BS; Pi, SY, 2010) |
| "Pulmonary edema has been demonstrated in the early stages of respiratory distress syndrome in premature infants." | 2.65 | Early furosemide therapy in premature infants (less than or equal to 2000 gm) with respiratory distress syndrome: a randomized controlled trial. ( Leu, ST; Pildes, RS; Raval, D; Shibli, A; Yeh, TF, 1984) |
| "During the study, the incidence of patent ductus arteriosus was significantly higher (P less than 0." | 2.65 | Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. ( Green, TP; Johnson, DE; Lock, JE; Thompson, TR, 1983) |
| " Dosing regimens of frusemide, and acetaminophen, and the sizes of ductus arteriosus following treatment, were evaluated." | 1.62 | Intravenous frusemide does not interact pharmacodynamically with acetaminophen in critically ill preterm neonates with patent ductus arteriosus. ( Al Ansari, E; Al Jufairi, M; Al Madhoob, A; Al Marzooq, R; Sridharan, K, 2021) |
| "Furosemide was prescribed to 4055 (9%) infants." | 1.48 | Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight. ( Bell, N; Clark, RH; Crowell, A; Greenberg, RG; Harrison, L; Hornik, CP; Kumar, K; Laughon, M; Scales, G; Shaw, L; Smith, PB; Thompson, EJ, 2018) |
| "All VLBW infants examined for hearing impairment were included and data were retrieved retrospectively and analyzed for neonatal risk factors using logistic regression." | 1.46 | Prevalence and independent risk factors for hearing impairment among very low birth weight infants. ( Chiang, MC; Chu, SM; Fu, RH; Hsu, JF; Lien, R; Wang, CH; Yang, CY, 2017) |
| "Furosemide was also s." | 1.36 | In vivo dilatation of the ductus arteriosus induced by furosemide in the rat. ( Momma, K; Nakanishi, T; Toyoshima, K, 2010) |
| "Symptomatic patent ductus arteriosus (sPDA) may occur in up to 50% of very-low-birth-weight (VLBW, less than or equal to 1500 g) infants." | 1.28 | Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989. ( Mouzinho, AI; Risser, R; Rosenfeld, CR, 1991) |
| "Furosemide is a known stimulant of the renal release of prostaglandin E2, a potent dilator of the ductus arteriosus." | 1.26 | Furosemide use in premature infants and appearance of patent ductus arteriosus. ( Green, TP; Johnson, D; Lock, JE; Thompson, TR, 1981) |
| "An infant with Ebstein's malformation of the tricuspid valve and severe pulmonic stenosis underwent a 39-day course of prostaglandin E1 infusion, and a histologic study of the ductus arteriosus was undertaken after autopsy." | 1.26 | Prolonged prostaglandin E1 infusion: histologic effects on the patent ductus arteriosus. ( Abman, S; Aziz, KU; Bharati, S; Cole, RB; Lev, M, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (53.49) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 3 (6.98) | 29.6817 |
| 2010's | 10 (23.26) | 24.3611 |
| 2020's | 3 (6.98) | 2.80 |
| Authors | Studies |
|---|---|
| Dudley, S | 1 |
| Sen, S | 1 |
| Hanson, A | 1 |
| El Khuffash, A | 1 |
| Levy, PT | 1 |
| Iacobelli, S | 1 |
| Lorrain, S | 1 |
| Gouyon, B | 1 |
| Gambacorta, S | 1 |
| Laforgia, N | 1 |
| Gouyon, JB | 1 |
| Bonsante, F | 1 |
| Sridharan, K | 1 |
| Al Madhoob, A | 1 |
| Al Jufairi, M | 1 |
| Al Ansari, E | 1 |
| Al Marzooq, R | 1 |
| Zung, A | 1 |
| Bier Palmon, R | 1 |
| Golan, A | 1 |
| Troitzky, M | 1 |
| Eventov-Friedman, S | 1 |
| Marom, R | 1 |
| Keidar, R | 1 |
| Kats, N | 1 |
| Almashanu, S | 1 |
| Flidel-Rimon, O | 1 |
| Thompson, EJ | 1 |
| Greenberg, RG | 1 |
| Kumar, K | 1 |
| Laughon, M | 1 |
| Smith, PB | 1 |
| Clark, RH | 1 |
| Crowell, A | 1 |
| Shaw, L | 1 |
| Harrison, L | 1 |
| Scales, G | 1 |
| Bell, N | 1 |
| Hornik, CP | 1 |
| Seaton, R | 1 |
| Williams, C | 1 |
| Peredo, J | 1 |
| Arcinue, R | 1 |
| Kantak, A | 1 |
| Elkhwad, M | 1 |
| Wang, CH | 1 |
| Yang, CY | 1 |
| Lien, R | 1 |
| Chu, SM | 1 |
| Hsu, JF | 1 |
| Fu, RH | 1 |
| Chiang, MC | 1 |
| Andriessen, P | 1 |
| Struis, NC | 1 |
| Niemarkt, H | 1 |
| Oetomo, SB | 1 |
| Tanke, RB | 1 |
| Van Overmeire, B | 1 |
| Toyoshima, K | 1 |
| Momma, K | 1 |
| Nakanishi, T | 1 |
| Lee, BS | 1 |
| Byun, SY | 1 |
| Chung, ML | 1 |
| Chang, JY | 1 |
| Kim, HY | 1 |
| Kim, EA | 1 |
| Kim, KS | 1 |
| Pi, SY | 1 |
| Segar, JL | 1 |
| Pacifici, GM | 1 |
| Caivano, D | 1 |
| Birettoni, F | 1 |
| Fruganti, A | 1 |
| Rishniw, M | 1 |
| Knafelz, P | 1 |
| Moïse, NS | 1 |
| Porciello, F | 1 |
| Green, TP | 3 |
| Thompson, TR | 3 |
| Johnson, DE | 2 |
| Lock, JE | 3 |
| Yee, WF | 1 |
| Cataletto, M | 1 |
| Scarpelli, EM | 1 |
| Yeh, TF | 3 |
| Shibli, A | 1 |
| Leu, ST | 1 |
| Raval, D | 1 |
| Pildes, RS | 3 |
| de Sarasqueta, P | 1 |
| Segura-Roldán, MA | 1 |
| Valls, M | 1 |
| Lozano-González, CH | 1 |
| Russo, EA | 1 |
| Yu, VY | 1 |
| Knight, DB | 1 |
| Obeyesekere, HI | 1 |
| Mitvalsky, J | 1 |
| Goldsmith, MA | 1 |
| Bhatia, SS | 1 |
| Kanto, WP | 1 |
| Kutner, MH | 1 |
| Rudman, D | 1 |
| Cohen, JI | 1 |
| Wilks, A | 2 |
| Singh, J | 1 |
| Betkerur, M | 1 |
| Lilien, L | 1 |
| Hufnagle, KG | 1 |
| Khan, SN | 1 |
| Penn, D | 1 |
| Cacciarelli, A | 1 |
| Williams, P | 1 |
| Jaso, E | 1 |
| Tejedor, JC | 1 |
| Quero, J | 1 |
| Pérez Rodríguez, J | 1 |
| Agustí, B | 1 |
| Castro, J | 1 |
| García Frías, E | 1 |
| Johnson, D | 1 |
| Cole, RB | 1 |
| Abman, S | 1 |
| Aziz, KU | 1 |
| Bharati, S | 1 |
| Lev, M | 1 |
| van den Anker, JN | 1 |
| Romagnoli, C | 1 |
| Zecca, E | 1 |
| Papacci, P | 1 |
| De Carolis, MP | 1 |
| Giannini, R | 1 |
| Gallini, F | 1 |
| Tortorolo, G | 1 |
| Brion, LP | 3 |
| Campbell, DE | 3 |
| Cotton, RB | 2 |
| Stahlman, MT | 2 |
| Kovar, I | 2 |
| Catterton, WZ | 2 |
| Friedman, Z | 1 |
| Demers, LM | 1 |
| Marks, KH | 1 |
| Uhrmann, S | 1 |
| Maisels, MJ | 1 |
| Bender, HW | 1 |
| Graham, TP | 1 |
| Hall, GS | 1 |
| Helmsworth, JA | 1 |
| Schreiber, JT | 1 |
| Rosenkrantz, JG | 1 |
| Martin, LW | 1 |
| Baylen, BG | 1 |
| Kaplan, S | 1 |
| Mouzinho, AI | 1 |
| Rosenfeld, CR | 1 |
| Risser, R | 1 |
| Aranda, JV | 1 |
| Chemtob, S | 1 |
| Laudignon, N | 1 |
| Sasyniuk, BI | 1 |
| Vargas-Origel, A | 1 |
| Cruz-Anguiano, V | 1 |
| López-Montaño, E | 1 |
| Luken, J | 1 |
| Robertson, NR | 1 |
| Richardson, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease[NCT01721655] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2012-10-31 | Recruiting | ||
| A Retrospective Chart Review Evaluating the Impact of Steroid, Diuretic, and Fluid Use Practice Trends in Extreme Premature Infants at Risk for Bronchopulmonary Dysplasia (BPD) at a Single Center Neonatal Intensive Care Unit[NCT04971694] | 175 participants (Anticipated) | Observational | 2021-09-08 | Recruiting | |||
| Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis[NCT02469597] | Phase 2 | 46 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02469597)
Timeframe: Participants will be followed for the duration of hospital stay up to 1 week
| Intervention | Days (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | 3.1 |
| Placebo | 3.0 |
(NCT02469597)
Timeframe: 2 hours after medication adminstration
| Intervention | Percentage change in oxygen saturation (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -0.14 |
| Placebo | 0.2 |
(NCT02469597)
Timeframe: 4 hours after medication adminstration
| Intervention | Percentage change in oxygen saturation (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -0.19 |
| Placebo | 0.29 |
(NCT02469597)
Timeframe: Within 72 hours of medication administration
| Intervention | participants (Number) |
|---|---|
| Single Dose of Furosemide | 0 |
| Placebo | 0 |
(NCT02469597)
Timeframe: 2 hours after medication adminstration
| Intervention | Percentage change in respiratory rate (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -3.7 |
| Placebo | -1.7 |
(NCT02469597)
Timeframe: 4 hours after medication adminstration
| Intervention | Percentage change in respiratory rate (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -2.8 |
| Placebo | -5.4 |
8 reviews available for furosemide and Patency of the Ductus Arteriosus
| Article | Year |
|---|---|
The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants.
Topics: Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Pr | 2022 |
Neonatal diuretic therapy: furosemide, thiazides, and spironolactone.
Topics: Bronchopulmonary Dysplasia; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newbor | 2012 |
Neonatal diuretic therapy: furosemide, thiazides, and spironolactone.
Topics: Bronchopulmonary Dysplasia; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newbor | 2012 |
Neonatal diuretic therapy: furosemide, thiazides, and spironolactone.
Topics: Bronchopulmonary Dysplasia; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newbor | 2012 |
Neonatal diuretic therapy: furosemide, thiazides, and spironolactone.
Topics: Bronchopulmonary Dysplasia; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newbor | 2012 |
Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.
Topics: Acetazolamide; Bumetanide; Drug Therapy, Combination; Ductus Arteriosus, Patent; Extracorporeal Memb | 2012 |
Pharmacokinetics and renal function in preterm infants.
Topics: Betamethasone; Diuretics; Dopamine; Ductus Arteriosus, Patent; Furosemide; Gestational Age; Glomerul | 1996 |
Furosemide in indomethacin-treated infants--systematic review and meta-analysis.
Topics: Blood Urea Nitrogen; Body Water; Drug Therapy, Combination; Ductus Arteriosus, Patent; Furosemide; G | 1999 |
Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants.
Topics: Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; I | 2000 |
Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants.
Topics: Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; I | 2001 |
Furosemide and vitamin E. Two problem drugs in neonatology.
Topics: Acid-Base Imbalance; Anemia; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Diuresis; Ductus Arter | 1986 |
7 trials available for furosemide and Patency of the Ductus Arteriosus
| Article | Year |
|---|---|
Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period.
Topics: Acute Kidney Injury; Creatinine; Cyclooxygenase Inhibitors; Drug Interactions; Ductus Arteriosus, Pa | 2010 |
Diuresis and pulmonary function in premature infants with respiratory distress syndrome.
Topics: Chlorothiazide; Clinical Trials as Topic; Diuresis; Ductus Arteriosus, Patent; Furosemide; Humans; I | 1983 |
Early furosemide therapy in premature infants (less than or equal to 2000 gm) with respiratory distress syndrome: a randomized controlled trial.
Topics: Bronchopulmonary Dysplasia; Clinical Trials as Topic; Ductus Arteriosus, Patent; Furosemide; Humans; | 1984 |
Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome.
Topics: Chlorothiazide; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newborn; Kidney; Prostaglandi | 1983 |
Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus.
Topics: Drug Therapy, Combination; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; Infant, Newb | 1982 |
Furosemide does not prevent indomethacin-induced renal side effects in preterm infants.
Topics: Body Weight; Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Female; Furosemide; Ge | 1997 |
Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants.
Topics: Digoxin; Ductus Arteriosus, Patent; Economics, Medical; Furosemide; Humans; Infant, Newborn; Infant, | 1978 |
28 other studies available for furosemide and Patency of the Ductus Arteriosus
| Article | Year |
|---|---|
Drug exposure for PDA closure in France: a prospective, cohort-based, analysis.
Topics: Acetaminophen; Administration, Oral; Drug Resistance; Drug Utilization; Ductus Arteriosus, Patent; F | 2020 |
Intravenous frusemide does not interact pharmacodynamically with acetaminophen in critically ill preterm neonates with patent ductus arteriosus.
Topics: Acetaminophen; Administration, Intravenous; Critical Illness; Ductus Arteriosus, Patent; Female; Fur | 2021 |
Risk Factors for the Development of Delayed TSH Elevation in Neonatal Intensive Care Unit Newborns.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Cefotaxime; Cesar | 2017 |
Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight.
Topics: Ductus Arteriosus, Patent; Female; Furosemide; Hospitalization; Humans; Infant, Newborn; Infant, Pre | 2018 |
Comparative case studies: PDAs treated with medication, surgical ligation, and transcatheter device closure.
Topics: Cardiac Catheterization; Cardiac Surgical Procedures; Cyclooxygenase Inhibitors; Diuretics; Ductus A | 2019 |
Acute kidney injury in ELBW infants (< 750 grams) and its associated risk factors.
Topics: Abruptio Placentae; Acute Kidney Injury; Adult; Amphotericin B; Anti-Bacterial Agents; Case-Control | 2015 |
Prevalence and independent risk factors for hearing impairment among very low birth weight infants.
Topics: Anti-Bacterial Agents; Craniofacial Abnormalities; Diuretics; Ductus Arteriosus, Patent; Evoked Pote | 2017 |
Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus.
Topics: Cohort Studies; Creatinine; Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Female; | 2009 |
In vivo dilatation of the ductus arteriosus induced by furosemide in the rat.
Topics: Animals; Animals, Newborn; Cesarean Section; Cyclooxygenase Inhibitors; Dilatation, Pathologic; Dise | 2010 |
Transthoracic echocardiographically-guided interventional cardiac procedures in the dog.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Balloon Valvuloplasty; Benzazepines; Cardiotonic | 2012 |
New concepts in neonatal respiratory distress syndrome.
Topics: Ductus Arteriosus, Patent; Female; Fetal Organ Maturity; Fluid Therapy; Furosemide; Humans; Infant, | 1984 |
[Echocardiographic study of the persistence of the ductus arteriosus in premature newborn infants].
Topics: Digoxin; Ductus Arteriosus, Patent; Echocardiography; Furosemide; Humans; Infant, Newborn; Infant, P | 1984 |
Iatrogenic metabolic alkalosis with respiratory alkalosis in a dog with patent ductus arteriosus.
Topics: Alkalosis; Alkalosis, Respiratory; Animals; Dog Diseases; Dogs; Ductus Arteriosus, Patent; Female; F | 1983 |
The management of patient ductus arteriosus in very low birthweight infants.
Topics: Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; Infant; Infant, Low Birth Weight; Infan | 1983 |
Gluconate calcium therapy and neonatal hypercalciuria.
Topics: Calcium; Calcium Gluconate; Creatinine; Ductus Arteriosus, Patent; Furosemide; Gluconates; Humans; I | 1981 |
Promotion of patent ductus arteriosus by furosemide.
Topics: Ductus Arteriosus, Patent; Female; Fetus; Furosemide; Humans; Infant, Newborn; Maternal-Fetal Exchan | 1983 |
Renal calcifications: a complication of long-term furosemide therapy in preterm infants.
Topics: Ductus Arteriosus, Patent; Furosemide; Heart Failure; Humans; Infant; Infant, Newborn; Infant, Prema | 1982 |
[Treatment of patent ductus arteriosus in preterm infants].
Topics: Digoxin; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Indomethacin; Infant, Low Birth Weig | 1982 |
Furosemide use in premature infants and appearance of patent ductus arteriosus.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Fluid Therapy; Furosemide; Humans; Infant, Newborn; Re | 1981 |
Prolonged prostaglandin E1 infusion: histologic effects on the patent ductus arteriosus.
Topics: Cardiac Catheterization; Digoxin; Ductus Arteriosus; Ductus Arteriosus, Patent; Ebstein Anomaly; Fem | 1981 |
Medical management of small preterm infants with symptomatic patent ductus arteriosus.
Topics: Blood Transfusion; Digoxin; Ductus Arteriosus, Patent; Furosemide; Heart Failure; Hematocrit; Humans | 1978 |
Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants.
Topics: Calcium; Drug Antagonism; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Hyaline Membrane Di | 1978 |
Premature infants with patent ductus arteriosus and respiratory distress: selection for ductal ligation.
Topics: Digitalis Glycosides; Ductus Arteriosus, Patent; Echocardiography; Female; Furosemide; Heart Failure | 1976 |
Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989.
Topics: Analysis of Variance; Cardiac Surgical Procedures; Colloids; Ductus Arteriosus, Patent; Female; Flui | 1991 |
[Indomethacin and furosemide in closure of ductus arteriosus].
Topics: Drug Evaluation; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Indomethacin; Infant, Newbor | 1986 |
Indomethacin therapy in premature infants with patent ductus arteriosus and oliguria.
Topics: Anuria; Drug Therapy, Combination; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; Infa | 1986 |
Prolonged continuous positive airways pressure for pulmonary oedema due to persistent ductus arteriosus in the newborn.
Topics: Carbon Dioxide; Cardiac Catheterization; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Infa | 1974 |
Frusemide in heart failure of infancy.
Topics: Administration, Oral; Aortic Coarctation; Body Weight; Chlorides; Ductus Arteriosus, Patent; Female; | 1971 |